Oncology Nursing Showdown! Aggressive Non–Hodgkin Lymphoma Edition: Module 2 - Mantel Cell Lymphoma

In the second segment of this three-part series, Maria Badillo, MSN, RN, OCN®, CCRP, Research Nurse Manager, MD Anderson Cancer Center, shares expert insights on guideline recommendations for optimizing individual patient care, efficacy and safety data, and strategies to manage adverse event for patients with advanced aggressive mantle cell lymphoma (MCL). For more expert insights on aggressive non-Hodgkin lymphoma, complete modules 1 and 3. Start the activity now!

Each year, 81,560 new cases of non-Hodgkin lymphoma (NHL) are diagnosed, and 20,720 people die of the disease (American Cancer Society, 2021). Mantle cell lymphoma (MCL), an aggressive form of NHL that is frequently diagnosed at a later stage of disease, makes up about 6% of all cases of NHL (Lymphoma Research Foundation, 2021). Patients with MCL have a median overall survival between 4 and 5 years (Leukemia & Lymphoma Society, 2020). Strategies for treating MCL vary based on patients’ symptoms and fitness, and MCL remains incurable despite recent advances (Schieber et al, 2018). Studies are underway to determine optimal strategies to treat MCL, and therapies including Bruton tyrosine kinase (BTK) inhibitors, B-cell lymphoma 2 (BCL2) inhibitors, chimeric antigen receptor (CAR) T-cell therapies, and bispecific T-cell engager (BiTe) antibodies are being investigated (Hanel & Epperla, 2020). It is vitally important for oncology nurses to gain up-to-date knowledge of guideline recommendations, clinical research advances, and adverse event management in order to provide optimal care to patients with this condition.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Evaluate guideline recommendations for the management of individual patients with advanced mantle cell lymphoma (MCL)
Assess emerging data on novel therapies for advanced aggressive MCLs
Apply strategies to manage adverse events and optimize treatment experiences for patients receiving novel therapies for advanced aggressive MCLs